N-Acetyl Semax Amidate

Mechanism

The most potent version of Semax, a Russian nootropic peptide originally developed for stroke recovery. The chemical modifications make it far more stable and better at crossing into the brain. In some lab tests, it raises BDNF (a key brain growth factor) up to 60 times more than standard Semax. Users report sharper focus, improved memory, and enhanced motivation.

Effects

NERVOUS SYSTEM (COGNITIVE ENHANCEMENT/NEUROPROTECTION): NA-Semax-Amidate is an enhanced version of Semax (Met-Glu-His-Phe-Pro-Gly-Pro, a synthetic analog of ACTH 4-10). N-acetyl and C-terminal amide modifications improve enzymatic stability and BBB penetration, resulting in longer duration of action and reportedly greater potency than standard Semax [in vitro, pharmacokinetic modeling, community experience]. BDNF ELEVATION: Semax is one of the most potent known stimulators of brain-derived neurotrophic factor — studies report up to 3-8x BDNF elevation in hippocampus and cortex in animal models at therapeutic doses [animal — Dolotov et al., 2006]. The "60x BDNF" claim circulating in the nootropic community appears to originate from a specific in vitro study on BDNF mRNA expression in certain cell types at specific timepoints — this is mRNA expression, not protein levels, in a specific in vitro system, NOT representative of whole-brain in vivo effects. Realistic BDNF elevation in vivo is likely 2-8x depending on brain region and timing [animal, context-adjusted]. NEUROPROTECTION: Reduces infarct volume in cerebral ischemia models by 25-40% [animal — Russian studies]. Mechanism: antioxidant (reduces lipid peroxidation, increases SOD and catalase), anti-apoptotic (upregulates Bcl-2, downregulates Bax and caspase-3), and neurotrophic (BDNF/NGF/GDNF elevation) [animal]. Protects against glutamate excitotoxicity [in vitro]. COGNITIVE: Enhances attention, memory consolidation, and learning in multiple animal behavioral models [animal]. Improves cognitive performance under stress conditions [animal, Russian clinical]. Modulates dopaminergic and serotonergic neurotransmission — increases dopamine and serotonin turnover in prefrontal cortex [animal]. NEUROVASCULAR: Promotes cerebral blood flow and angiogenesis in ischemic brain tissue [animal]. OPTIC NERVE: Semax has been studied for optic nerve neuroprotection (Russian clinical use for glaucoma and optic atrophy) — neurotrophic support via BDNF/CNTF elevation in retinal ganglion cells [animal, Russian clinical studies]. IMMUNE: Some immunomodulatory effects — modulates expression of immune-related genes, though less pronounced than Selank [animal].

Practitioner Guide

ADMINISTRATION: Intranasal is the primary route — highly effective for CNS delivery via olfactory pathway. Subcutaneous is alternative. DOSING: Intranasal 100-600 mcg/day, typically divided into 1-2 doses. Start at 100-200 mcg/day. Common dose: 300 mcg intranasal in the morning. High dose: 600 mcg/day (divided AM/PM). Duration of effect per dose: 6-12 hours (vs. 3-6 hours for standard Semax — the NA-Amidate modifications roughly double duration). COMPARISON TO STANDARD SEMAX: NA-Semax-Amidate users consistently report stronger and longer-lasting cognitive effects compared to standard Semax. Estimated equipotent at roughly half the dose of standard Semax (i.e., 300 mcg NA-Semax-Amidate ≈ 600 mcg standard Semax). The enhanced form may have better BBB penetration and is more resistant to peptidase degradation. CYCLING: Recommended: 5 days on/2 days off, or 3 weeks on/1 week off. Standard Semax in Russian clinical use is prescribed in 10-14 day courses with breaks. Continuous use is practiced by some in the nootropic community but cycling is advisable given the potent neurotrophic effects (chronic BDNF elevation effects unknown long-term). STACKING: Classic stack: NA-Semax-Amidate (cognitive/BDNF) + NA-Selank-Amidate (anxiolytic/mood) — this combination is one of the most popular in the nootropic peptide community. Additional stacking: with racetams (piracetam 2.4-4.8g/day — complementary mechanisms), lion's mane mushroom (500-1000mg — additional NGF stimulation), omega-3/DHA (brain structural support), alpha-GPC (300-600mg — acetylcholine precursor). For intensive cognitive work: combine with modafinil or caffeine + L-theanine. THE 60x BDNF CLAIM — IMPORTANT CONTEXT: Many nootropic vendors market "60x BDNF increase." This is misleading. The original data showed mRNA expression changes in specific experimental conditions. Realistic expectations: meaningful BDNF elevation (several-fold) that supports neuroplasticity and neuroprotection, but not a 60-fold protein increase in the whole brain. Still one of the most potent known BDNF stimulators in peptide form — just calibrate expectations. SOURCING: Available from research peptide suppliers. Quality varies — demand HPLC and mass spec certificates. Typically supplied lyophilized or as pre-made nasal spray. STORAGE: Lyophilized: -20°C for long-term, room temperature stable for months. Reconstituted: 2-8°C, use within 4-6 weeks. Use bacteriostatic water. SAFETY: Based on Semax's Russian clinical approval (1996 — nasal spray for stroke, cognitive impairment, optic nerve disease) and extensive community use, the safety profile is favorable. Rare side effects: mild headache, transient hair shedding (reported anecdotally — possibly related to BDNF/neurotrophin effects on hair follicle cycling), nasal irritation, and mild irritability at high doses. No serious adverse effects reported. CAUTION: Theoretically could exacerbate anxiety in sensitive individuals (dopaminergic/adrenergic activation) — start low. If anxiety occurs, reduce dose or add NA-Selank-Amidate to counterbalance.

Evidence

• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats

  Glazova NY, Manchenko DM, Volodina MA, Merchieva SA, Andreeva LA, Kudrin VS, Myasoedov NF, Levitskaya NG (2021) — Neuropeptides — PMID: 33418449

  Semax administration reduced anxiety-like behavior, improved learning, and normalized brain biogenic amines disrupted by early-life SSRI (fluvoxamine) exposure. Demonstrated neuroprotective effect against serotonin system disruption during development. Supports Semax as modulator of anxiety-related monoamine systems.

  moderate

• Functional Connectomic Approach to Studying Selank and Semax Effects

  Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF (2020) — Dokl Biol Sci — PMID: 32342318

  Selank and Semax both altered resting-state fMRI functional connectivity between right amygdala and temporal cortex within 20 minutes of intranasal administration in 52 healthy participants. Each peptide showed distinct connectivity patterns — Selank predominantly anxiolytic (amygdala-focused); Semax more prefrontal/executive (DLPFC). First direct neuroimaging evidence of distinct mechanisms.

  moderate

• Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action

  Levitskaia NG, Vilenskii DA, Sebentsova EA, Andreeva LA, Kamenskii AA, Miasoedov NF (2010) — Izv Akad Nauk Ser Biol — PMID: 20387390

  Intranasal Semax (50-500 mcg/kg) normalized anxiety and depression behaviors elevated by cholecystokinin-tetrapeptide (CCK-4). No effect on baseline emotional state in normal rats. Anxiolytic and antidepressant effects observed specifically at elevated anxiety levels — suggests condition-specific activation rather than general sedation.

  moderate

Research Summary

TIER 1: No RCTs on NA-Semax-Amidate specifically. Semax (parent compound) has Russian regulatory approval (1996) for: acute ischemic stroke (nasal spray, used in ambulances), cognitive disorders, optic nerve atrophy. Russian Phase II/III clinical trials showed improved neurological outcomes in stroke and cognitive improvement in cerebrovascular disease patients. These trials do not fully meet ICH-GCP standards. TIER 2: Preclinical studies on Semax: BDNF/NGF/GDNF elevation in multiple brain regions (Dolotov et al., 2006; Agapova et al., 2008). Neuroprotection in cerebral ischemia models (25-40% infarct reduction). Gene expression profiling — Semax modulates hundreds of genes related to neurotrophic support, immune function, and vascular remodeling (Dolotov et al., 2006; Medvedeva et al., 2014). Reviews of melanocortin peptides and ACTH fragments as nootropics. Pharmacokinetic studies of modified Semax analogs. TIER 3: Extensive nootropic community experience (Reddit, Longecity — one of the most-discussed nootropic peptides with thousands of experience reports over 10+ years). Russian clinical practitioner experience spanning decades. International biohacking community consensus: reliably effective for cognitive enhancement, focus, and motivation with good tolerability. Among the most well-validated nootropic peptides by community experience. KEY FINDINGS: Semax is arguably the best-supported nootropic peptide — Russian clinical approval, extensive preclinical data, and massive community experience all converge on genuine cognitive-enhancing and neuroprotective effects. NA-Semax-Amidate is the community-preferred form for its improved potency and duration. The BDNF elevation is real and meaningful, though the "60x" marketing claim is exaggerated. GAPS: No Western clinical trials. PK/PD data for NA-Semax-Amidate in humans not available. Optimal chronic dosing unknown. Long-term effects of sustained BDNF elevation unstudied. Comparison to NA-Semax-Amidate vs. standard Semax not formally studied. ACTIVE TRIALS: Limited on ClinicalTrials.gov. Semax continues to be studied at the Institute of Molecular Genetics, Russian Academy of Sciences. Some interest in Semax for TBI and neurodegenerative conditions in Russian research.